Print

ACCU-BREAK Pharmaceuticals, Inc. Enters Into a Product Development and License Agreement With Alembic Pharmaceuticals Limited  
8/6/2012 9:32:46 AM

PLANTATION, Fla.--(BUSINESS WIRE)--Accu-Break Pharmaceuticals, Inc. (“ABP”) announced today that it has entered into a development and license agreement with Alembic Pharmaceuticals Limited of Gujarat, India to develop new brand products that will use ABP’s innovative Accu-Break™ tablet technologies. ABP’s patented Accu-Break tablets can be split easily by hand into exact smaller doses to provide maximum flexibility, and to make it easier and safer for patients and caregivers to adjust their dosage. The first product that ABP will seek Food and Drug Administration marketing approval for is an Accu-Break-formatted version of the popular anticoagulant medication warfarin (Coumadin®).
//-->